Predictive value of osteocalcin and β-CrossLaps in metastatic breast cancer

Salem, Ahmed M.; Zohny, Samir F.; El-Wahab, Manal M. Abd; Hamdy, Rehab M.

doi:10.1016/j.clinbiochem.2007.07.006

Cited by 13 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…bone, represents an accurate and effective diagnostic test to measure metastasis-associated bone degradation in patients. (35) Using this approach, our studies show that plasma levels of CXCL12 strongly correlate with a serum marker of bone loss and confirm the association between CXCL12 and osteolysis.…”

Section: Discussionsupporting

confidence: 71%

“…In this study, the correlation between plasma CXCL12 levels and bone loss was confirmed by assessing plasma βCrossLaps levels. Assessment of βCrossLap levels in sera, a measure of collagen I breakdown products from bone, represents an accurate and effective diagnostic test to measure metastasis‐associated bone degradation in patients (35) . Using this approach, our studies show that plasma levels of CXCL12 strongly correlate with a serum marker of bone loss and confirm the association between CXCL12 and osteolysis.…”

Section: Discussionsupporting

confidence: 55%

See 1 more Smart Citation

Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss

Diamond

Labrinidis

Martin

et al. 2009

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

The plasma cell (PC) malignancy, multiple myeloma (MM), is unique among hematological malignancies in its capacity to cause osteoclast (OC)-mediated skeletal destruction. We have previously shown that elevated plasma levels of PC-derived CXCL12 are associated with presence of X-ray detectable osteolytic lesions in MM patients. To further investigate this relationship, plasma levels of CXCL12 and bCrossLaps, a marker of bone loss, were measured. A strong correlation between levels of CXCL12 and OCmediated bone resorption was identified. To confirm the OC-activating potential of MM PC-derived CXCL12 in vivo, we established a model of MM-mediated focal osteolysis, wherein MM PC lines, such as RPMI-8226, were injected into the tibias of nude mice. Implanting RPMI-8226 gave rise to osteolytic lesions proximal to the tumor, resulting in a 5% decrease in bone volume (BV) compared with vehicle control. Importantly, bone loss was significantly inhibited with systemic administration of the CXCL12/CXCR4 antagonist T140. Furthermore, implanting CXCL12-overexpressing RPMI-8226 cells resulted in a 13% decrease in BV and was associated with increased OC recruitment proximal to the tumor, increased serum matrix metalloproteinase activity, and increased levels of collagen I degradation products. These findings confirm our hypothesis that MM PC-derived CXCL12 stimulates the recruitment and activity of OC, thereby contributing to the formation of MM osteolytic lesions.

show abstract

Section: Discussionsupporting

confidence: 71%

Section: Discussionsupporting

confidence: 55%

Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss

Diamond

Labrinidis

Martin

et al. 2009

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…It is clear from the previous studies that neither a single gene, nor a single pathway, governs metastasis of breast cancer to bone [reviewed in references 1, 2]. Our laboratory was participated in studying factors involved in bone metastatic breast cancer [3]; however, the identification of additional factors is crucial to explore effective therapies that might improve the outcome of the disease.…”

Section: Introductionmentioning

confidence: 97%

Significance of survivin and Bcl-2 homologous antagonist/killer mRNA in detection of bone metastasis in patients with breast cancer

Zohny

El-Shinawi

2010

Med Oncol

Self Cite

View full text Add to dashboard Cite

The aim of this study was to assess the diagnostic value of survivin and Bcl-2 homologous antagonist/killer (Bak) mRNA in the detection of patients with bone metastatic breast cancer. This study included 92 patients with breast carcinoma (54 non-metastatic and 38 bone metastatic) and 31 patients with benign breast lesions. Survivin in cell lysates was measured by ELISA while tissue Bak mRNA was detected by RT-PCR. Survivin was significantly increased in bone metastatic breast cancer patients compared to non-metastatic cases or benign ones. Bak mRNA was markedly decreased in bone metastatic patients compared to non-metastatic ones, while significant expression of Bak mRNA was observed in bone metastatic cases compared to benign patients. High survivin level was associated with high grade, late stages and lymph node involvement, whereas low Bak mRNA was associated with late stages. Our data indicate that survivin and Bak mRNA were considerable markers for the identification of breast cancer patients with bone metastasis.

show abstract

“…They found that the level of osteocalcin was high 50 % of patients (Kamby et al, 1993). Salem et al evaluated statistically high osteocalcin levels in the study with 47 breast cancer patients and they found that osteocalcin levels in patients with metastatic lesions were higher than the levels in non-metastatic patients (Salem et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

Markers of Bone Metastases in Breast and Lung Cancers

Bilgin

Yasasever²,

Soydinc³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Aim and Background: The aim of the present study was to evaluate correlations between serum osteocalcin, osteoprotegerin and NTX (Cross-linked N-telopeptides of Type I Collagen) and urinary NTX in breast and lung cancer patients with bone metastases. These four markers are considered to have important roles in bone formation, resorption and metastases. Methods: Four markers were determined in the sera of 60 breast cancer and 21 lung cancer patients and healthy controls (n=30). Serum levels were studied using ELISA and EIA. Results: The median levels of serum osteoprotegerin (p<0.001) and osteocalcin (p=0.003) were higher in patients. Significant correlations were observed between the serum NTX-osteocalcin (r=0.431; p<0.001), serum NTXosteoprotegerin (r=0.42; p=0.003) and serum NTX -urine NTX (r=0.255; p=0.022). Conclusion: We conclude that osteocalcin, osteoprotegerin and NTX are independent diagnostic tools. Due to the ease of urine collection, urine NTX may be applied routinely to allow early detection of bone metastases and indicate progression of the disease.

show abstract

Predictive value of osteocalcin and β-CrossLaps in metastatic breast cancer

Cited by 13 publications

References 23 publications

Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss

Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss

Significance of survivin and Bcl-2 homologous antagonist/killer mRNA in detection of bone metastasis in patients with breast cancer

Markers of Bone Metastases in Breast and Lung Cancers

Contact Info

Product

Resources

About